Company profile: Anaveon
1.1 - Company Overview
Company description
- Provider of IL-2-based immunotherapies developing selective IL-2 complexes that promote effector T cell functions as immune adjuvants for cancer, with candidates including ANV419, an IL-2 agonist that favors effector over regulatory T cells and shows clinical efficacy, and ANV600, a bispecific targeting IL-2 to tumor-specific cells, with Phase 1/2 planned for Q2/2024.
Products and services
- IL-2 Complex Platform: architects immune-adjuvant IL-2 complexes with a broad therapeutic window that selectively enhance effector T cell functions, showing marked preclinical anti-cancer efficacy as monotherapy or combined therapies
- ANV419: engineers a clinical-stage IL-2 agonist for cancer therapy that selectively promotes proliferation of effector T cells over regulatory T cells, exhibiting efficacy in clinical trials
- ANV600: architects a bispecific molecule directing IL-2 to tumor-specific cells to enhance their proliferation and tumor-killing potential, with a Phase 1/2 study expected to start in Q2/2024
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Anaveon
Immunitas Therapeutics
HQ: United States
Website
- Description: Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunitas Therapeutics company profile →
Blaze Bioscience
HQ: United States
Website
- Description: Provider of products that assist surgeons treating cancer patients, including BLZ-100 (tozuleristide), a fluorescent imaging agent used in brain cancer surgery to help visualize tumors, and the CANVAS Imaging System, used in conjunction with BLZ-100 to detect and visualize tumors during surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blaze Bioscience company profile →
Seagen
HQ: United States
Website
- Description: Provider of monoclonal antibody-based therapies and advanced antibody-drug conjugate technology focused on improving patient outcomes in cancer and autoimmune diseases. Lead program SGN-35 is in a pivotal trial for patients with relapsed or refractory Hodgkin lymphoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seagen company profile →
Silverback Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing ImmunoTAC treatments targeting previously inaccessible disease pathways, and a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silverback Therapeutics company profile →
Totient
HQ: United States
Website
- Description: Provider of AI-driven biotechnology leveraging tertiary lymphoid structures to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics, using machine learning and immunoinformatics to pull critical insights from large, complex datasets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Totient company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Anaveon
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Anaveon
2.2 - Growth funds investing in similar companies to Anaveon
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Anaveon
4.2 - Public trading comparable groups for Anaveon
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →